Literature DB >> 21383652

The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.

David Burger1, Marga Teulen, Jaco Eerland, Anneke Harteveld, Rob Aarnoutse, Daan Touw.   

Abstract

The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma was initiated in 1999 by Radboud University Nijmegen Medical Center, The Netherlands, and continued later on in collaboration with the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology (www.kkgt.nl). The aim of this analysis was to evaluate the first 10 years of the Program and to determine variables associated with reporting of less accurate results. Two rounds are organized annually in which blind samples are shipped to participants containing a low, medium, or high concentration of each antiretroviral drug. Any reported result that deviates more than 20% from the spiked concentration is defined as inaccurate. By the end of 2009, the number of laboratories participating in the Program had increased to 56; 44 (79%) are located in Europe. A total of 12,798 test results was available for analysis, of which 2104 (16.4%) were reported as inaccurate. Performance was best for samples containing nevirapine (mean of inadequate scores per round: 11.1%) and lopinavir (11.9%) and worst for indinavir (18.7%), atazanavir (18.9%), saquinavir (19.6%), and nelfinavir (21.3%). High and medium concentrations were less frequently reported as inaccurate than low concentrations: 13.5%, 13.0%, and 22.4%, respectively. Although the overall performance of the laboratories varied per year, a trend was visible for improvement over time with 19.9% of the results being inaccurate in 2002 (n = 20 laboratories) to 15.7% in 2009 (n = 56 laboratories). The Program provides a proficiency testing program in which laboratories are alerted to potential analytical errors while performing therapeutic drug monitoring in HIV-infected patients. Laboratories should put more effort in adequately analyzing concentrations of antiretroviral drugs with low minimum effective concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383652     DOI: 10.1097/FTD.0b013e31820fa528

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  13 in total

1.  Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.

Authors:  Maren Blonk; Angela Colbers; Anne Poirters; Bas Schouwenberg; David Burger
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

2.  Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line Antiretroviral Therapy in Asia.

Authors:  Linda Aurpibul; Sirinya Teerananchai; Wasana Prasitsuebsai; Tavitiya Sudjaritruk; Pope Kosalaraksa; Nia Kurniati; Khanh Huu Truong; Viet Chau Do; Lam Van Nguyen; Kulkanya Chokephaibulkit; Thida Singtoroj; Stephen J Kerr
Journal:  Ther Drug Monit       Date:  2016-12       Impact factor: 3.681

3.  Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories.

Authors:  Robin DiFrancesco; Susan L Rosenkranz; Charlene R Taylor; Poonam G Pande; Suzanne M Siminski; Richard W Jenny; Gene D Morse
Journal:  Ther Drug Monit       Date:  2013-10       Impact factor: 3.681

4.  Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for Antiretrovirals.

Authors:  Richard W Browne; Susan L Rosenkranz; Yan Wang; Charlene R Taylor; Robin DiFrancesco; Gene D Morse
Journal:  Ther Drug Monit       Date:  2019-08       Impact factor: 3.681

5.  Adding value to antiretroviral proficiency testing.

Authors:  Robin DiFrancesco; Charlene R Taylor; Susan L Rosenkranz; Kelly M Tooley; Poonam G Pande; Suzanne M Siminski; Richard W Jenny; Gene D Morse
Journal:  Bioanalysis       Date:  2014-10       Impact factor: 2.681

Review 6.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

7.  Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.

Authors:  Adrian Curran; Ramon Martí; Rosa María López; Mercè Pérez; Manel Crespo; María Jesús Melià; Jordi Navarro; Joaquín Burgos; Vicenç Falcó; Inma Ocaña; Esteban Ribera
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

8.  Development of a proficiency testing program for the HIV-1 BED incidence assay in China.

Authors:  Hao Yan; Haiying Yu; Wenge Xing; Yao Xiao; Hui Zhang; Lijian Pei; Na Zhang; Yan Jiang
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

9.  Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.

Authors: 
Journal:  AIDS       Date:  2015-11-28       Impact factor: 4.177

10.  Risk factors contributing to a low darunavir plasma concentration.

Authors:  Alper Daskapan; Ymkje Stienstra; Jos G W Kosterink; Wouter F W Bierman; Tjip S van der Werf; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Br J Clin Pharmacol       Date:  2017-12-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.